Kodiak Sciences stock soars over 60%: what’s behind the sharp rally

Shares of Kodiak Sciences surged sharply on Thursday after the biotechnology company reported positive results from a late-stage study of its experimental drug for diabetic retinopathy, a diabetes-related eye condition.

The stock jumped as much as 68.6% to its highest level in more than four years, reflecting strong investor optimism following the announcement.

At the time of writing, the stock was trading at $36.50, trading up by 60%.

The company had a market valuation of $1.39 billion as of Wednesday’s close.

Kodiak’s experimental therapy, Zenkuda, is being developed to treat diabetic retinopathy, a progressive condition caused by damaged blood vessels in the retina that can lead to leakage, bleeding, and potential vision loss.

Strong efficacy results in late-stage trial

Kodiak said its late-stage trial met its primary endpoint, demonstrating significant improvement in patients treated with Zenkuda compared with a placebo.

According to the company, 62.5% of patients receiving the drug achieved at least a two-step improvement on a standard retinopathy severity scale at 48 weeks, compared with just 3.3% of patients receiving a placebo treatment.

Zenkuda also showed strong performance on secondary measures.

Patients treated with the drug experienced an 85% reduction in the risk of developing sight-threatening complications, including progression to proliferative diabetic retinopathy.

The company said the results indicate that Zenkuda was superior to placebo across both primary and secondary endpoints.

Safety profile and platform validation

Kodiak highlighted that Zenkuda was well-tolerated in the study, with no reported cases of serious vision-threatening side effects such as inflammation of blood vessels or the eye.

The drug is designed as a long-acting therapy that blocks a protein associated with abnormal blood vessel growth in the retina.

It is built on the company’s antibody-biopolymer conjugate (ABC) platform, a key component of Kodiak’s broader drug development strategy.

Analysts noted that the positive trial outcomes could have implications beyond the single drug.

JP Morgan analyst Anupam Rama said the strong data could boost confidence in the company’s ABC platform and its broader pipeline.

Kodiak also reported that the drug demonstrated consistent efficacy regardless of whether patients were using GLP-1 medications, suggesting broad applicability across different patient groups.

Regulatory path and future outlook

Following the positive results, Kodiak said it plans to accelerate its application for regulatory approval with the US Food and Drug Administration.

Chief Executive Victor Perlroth said the company is encouraged by the outcome of the study and intends to speed up its biologics license application, or BLA, submission plans.

The strong safety and efficacy data may also reduce uncertainty around Kodiak’s broader clinical pipeline. UBS analyst Michael Yee noted that the results could de-risk the company’s ongoing study in wet age-related macular degeneration, which is expected to deliver results in the third quarter.

Kodiak’s rapid share price gains reflect investor confidence that Zenkuda could become a significant treatment option in diabetic eye disease, while also validating the company’s underlying technology platform.

As the company moves toward regulatory submission, market attention is likely to remain focused on the approval timeline and the potential commercial opportunity for the drug in a large and growing patient population.